KONEXBiotech & Pharma215570

Cronex

₩590▼ 0.67%2026-11-18 close
Market Cap
₩3.9B
Turnover
₩102,862
Volume
202 shares
Shares out.
6.7M
PER
—
PBR
—
EPS
—
Dividend Yield
0.00%

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Operating profit, net loss

Cronex posted operating profit for FY2025 on a standalone basis, but a net loss kept its earnings base unsettled.

  1. 1

    On a standalone basis, FY2025 operating profit was KRW 642 million, but the net loss of KRW 2,569 million left the bottom line in the red.

  2. 2

    Non-clinical CRO services and mini-pig biological supply form the core business, while biomaterials and xenotransplantation are positioned as medium- to long-term businesses.

  3. 3

    At year-end 2025, total liabilities of KRW 12,371 million were large relative to total equity of KRW 1,867 million.

  4. 4

    The operation of the Jeju native pig genetic resource center and a stated target of KRW 50 billion in revenue within three years are the key variables for future results.

  5. 5

    As of the September 30, 2026 close of KRW 599, the 52-week share price change was -33.26%, and trading volume and free float were small.

02

Business structure

Cronex was founded in May 2012 and listed on the KONEX market in December 2015. Its core businesses are non-clinical efficacy evaluation services (CRO) used in drug and medical device development and the supply of biological species such as research mini-pigs.

The company is developing a biomaterial business that uses mini-pig tissue to replace or regenerate damaged human tissue, which it positions as a higher-value segment. Its xenotransplantation research aims to develop mini-pigs with immune-rejection genes removed, using CRISPR-Cas12 gene-editing technology.

In July 2019, the Ministry of Food and Drug Safety designated its facility as an excellent laboratory animal production facility, equipped with a clean room and an in-house pathogen verification system.

Its non-clinical sites include a research institute in Cheongju, a non-clinical testing center in Suwon prepared in 2022, and a mini-pig research facility in Jeju. The Suwon center provides efficacy analysis services for cosmetics, medical devices, pharmaceuticals, and health functional foods.

Past reports described Cronex as having one of the largest mini-pig production capacities in Korea, where domestic supply is scarce. For xenotransplantation, United Therapeutics in the US and Genen Biotech in Korea were cited as comparison companies in a 2021 report.

The company has said it will strengthen its financial base through CRO and biological species sales while preparing for a fuller expansion into xenotransplantation.

03

Recent trends

At the annual general meeting held on March 31, 2026, shareholders approved the FY2025 (14th term) financial statements. On a standalone basis disclosed the same day, FY2025 revenue was KRW 5,534 million and operating profit was KRW 642 million.

However, the net loss reached KRW 2,569 million, so the operating profit did not carry through to the bottom line. At year-end 2025, total assets were KRW 14,238 million, total liabilities KRW 12,371 million, and total equity KRW 1,867 million.

A market data aggregator shows FY2025 revenue of KRW 5,892 million, which differs from the disclosed figure. On the same aggregator basis, FY2024 revenue was KRW 452.76 million, down 3.17% year on year.

On that basis, operating cash flow was negative, with cash and equivalents of about KRW 280.94 million and debt of about KRW 200 million. The share price moved from KRW 1,259 intraday on March 31, 2026 to a KRW 599 close on September 30, 2026.

On the same aggregator basis, the 52-week share price change was -33.26%, and the price-to-book ratio was 4.80x. As of November 11, 2026, the share price stood at KRW 600 and the market capitalization at KRW 4.0 billion.

04

Outlook

The key factor for future results is how much contribution the Jeju native pig genetic resource center, announced for completion at the end of 2025, makes to revenue from 2026. The company has said the center will support its entry into the medical device market based on high-purity collagen.

Based on operations at the Jeju center, the company set a medium- to long-term target of KRW 50 billion in revenue within three years from CRO and bio-resource income, as reported in 2025.

Compared with FY2025 standalone revenue of KRW 5,534 million, the gap to that target is large, so the path to it will depend on Jeju center revenue and the scale of new CRO contracts.

A 2025 report said the company planned to select a listing underwriter by the end of October 2025 and begin preparations for a KOSDAQ listing. The company has also said it has been upgrading internal accounting and legal systems and quality control standards during this preparation.

Because total equity is thin relative to total assets, reducing the net loss and strengthening capital will be indicators of financial stability. Since operating profit turned positive in FY2025, the next checkpoints are whether that profit repeats and how the disclosures explain the cause of the net loss.

Xenotransplantation and biomaterial businesses require long clinical and regulatory stages, so they remain medium- to long-term tasks that are unlikely to show up in near-term results.

05

Bull factors

Recovery in non-clinical CRO revenue

On a market data aggregator basis, FY2024 revenue fell 3.17% year on year, but FY2025 revenue is shown rising again to KRW 5,892 million. A past report cited a 36% average annual revenue growth rate since the 2015 listing.

The company said its customer base and cooperation network have expanded, steadily increasing its revenue sources. According to the company, non-clinical CRO and biological species sales serve as its financial foundation.

Operating profit recorded

On a standalone basis, FY2025 operating profit was KRW 642 million, a positive result. Profit at the operating level suggests that the basic earnings structure of the CRO and biological species businesses is functioning.

On the aggregator basis, the gross margin was 62.64%, which points to some room in the cost structure. The operating margin was 9.50% on the same basis, indicating that profitability centered on core operations is being maintained.

Jeju mini-pig production base

The company operates a production system designated in July 2019 as an excellent laboratory animal production facility. The Jeju native pig genetic resource center was announced for completion at the end of 2025, with operations planned from 2026.

The center is described as serving two functions: outsourced CRO work for external clients and verification of the company's own products. According to the company, this base can connect to raw material supply capacity for its biomaterial and xenotransplantation businesses.

06

Bear factors

Net loss and thin equity

The FY2025 net loss of KRW 2,569 million was large relative to operating profit of KRW 642 million. Total equity was KRW 1,867 million, while total liabilities were KRW 12,371 million, a heavy debt load. On the aggregator basis, the debt ratio was 88.98%, which indicates limited financial capacity.

The high share of liabilities within total assets of KRW 14,238 million at year-end 2025 is the core of the financial burden.

Gap between target and results

The three-year target of KRW 50 billion in revenue is far larger than FY2025 standalone revenue of KRW 5,534 million. Reaching the target will require commercial operation at the Jeju center and an expanded pipeline of new CRO contracts at the same time. On the aggregator basis, revenue also declined in FY2024.

Since xenotransplantation commercialization timing depends on clinical and regulatory steps, the timeline for the medium- to long-term target carries uncertainty as well.

Share price weakness and thin liquidity

The share price fell from an intraday KRW 1,259 on March 31, 2026 to a KRW 599 close on September 30, 2026, and the 52-week change was -33.26%. On the aggregator basis, average trading volume was about 4,051 shares, which is thin, and free float is recorded at less than half of total shares outstanding. Insider ownership is shown at 35.22%. Under this structure, even small trades can move the price significantly.

07

Risk factors

Regulatory

Laboratory animal production and non-clinical testing operate under facility designations and quality standards set by the Ministry of Food and Drug Safety.

Failure to maintain certification requirements, such as the excellent laboratory animal production facility designation, could affect the entire outsourced business. Tighter regulation of animal testing could also influence operating conditions. New licensing requirements could emerge during the operation of the Jeju center as well.

Funding

With debt large relative to equity, simultaneous spending on the Jeju center and listing preparation could increase the need for additional funding. In the past, the company relied on external capital, including private convertible bonds and a planned Series B round.

If financing conditions tighten, terms could become less favorable, and combined with the net loss this could increase financial pressure.

Macro

The biotech sector is sensitive to interest rates and shifts in investor sentiment, and KONEX-listed stocks with low liquidity can show large price swings. The wide gap between the 52-week high of KRW 2,300 and the recent share price reflects this characteristic.

The uncertain timing of xenotransplantation commercialization remains a sector-wide uncertainty. Changes in overall market capital flows can also affect the environment in which small biotech companies are priced.

08

Overall view

Cronex recorded operating profit at the operating level in FY2025 based on non-clinical CRO services and mini-pig biological supply, but the continued net loss means its earnings structure has not yet settled.

Its financial structure carries a thin equity base and a high debt ratio, and cash and debt levels are small on the aggregator basis.

The Jeju mini-pig center and biomaterial business are described by the company as potential medium- to long-term revenue bases, but the KRW 50 billion target is far above current revenue, so the path to it is not yet clear.

Bullish factors include whether operating profit repeats, the performance of the Jeju center, and the sustainability of the revenue recovery, while bearish factors include the ongoing net loss, the burden of the capital structure, and the gap to the target.

The share price has trended lower since March 2026, and thin trading liquidity makes it a stock with high price volatility. How these three factors appear in future disclosed figures will be the most direct input for assessment.

This report is provided for information purposes only and does not present an investment opinion or target price.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 9 more articles and sources
  1. news.nate.com
  2. hankyung.com
  3. biotimes.co.kr
  4. alphasquare.co.kr
  5. stockanalysis.com
  6. investing.com
  7. m.thebell.co.kr
  8. konex.or.kr
  9. biospectator.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis